항우울제 시장 : 약제 클래스별, 질환 유형별, 약제 유형별, 유통 채널별, 지역별(2026-2034년)

The global depression drugs market size reached USD 19.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 25.4 Billion by 2034, exhibiting a growth rate (CAGR) of 2.79% during 2026-2034. The growing cases of depression among the masses due to sedentary lifestyle and stress, increasing advancements in drug formulation and delivery techniques, and rising preferences for digital therapeutics, such as mobile apps and online therapy platforms, are some of the factors impelling the market growth.

Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.

According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years.

The latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2026-2034. Our report has categorized the market based on drug class, disorder type, drug type, and distribution channel.

Breakup by Drug Class:

• Atypical Antipsychotics
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Central Nervous System (CNS) Stimulants
• Tricyclic Antidepressants
• Monoamine Oxidase Inhibitors
• Others

Breakup by Disorder Type:

• Major Depressive Disorder
• Obsessive-Compulsive Disorder
• Generalized Anxiety Disorder
• Panic Disorder
• Others

Breakup by Drug Type:

• Generic Drugs
• Branded Drugs

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Breakup by Region:

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Key Questions Answered in This Report

• What is the size of the global depression drugs market?
• What has been the impact of COVID-19 on the global depression drugs market?
• What is the expected growth rate of the global depression drugs market?
• What are the key factors driving the global depression drugs market?
• What is the breakup of the global depression drugs market based on the disorder type?
• What is the breakup of the global depression drugs market based on the distribution channel?
• What are the key regions in the global depression drugs market?
• Who are the key companies/players in the global depression drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Depression Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Drug Class
• 5.5 Market Breakup by Disorder Type
• 5.6 Market Breakup by Drug Type
• 5.7 Market Breakup by Distribution Channel
• 5.8 Market Breakup by Region
• 5.9 Market Forecast

6 Market Breakup by Drug Class

• 6.1 Atypical Antipsychotics
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Central Nervous System (CNS) Stimulants
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Tricyclic Antidepressants
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Monoamine Oxidase Inhibitors
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Others
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by Disorder Type

• 7.1 Major Depressive Disorder
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Obsessive-Compulsive Disorder
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Generalized Anxiety Disorder
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Panic Disorder
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Drug Type

• 8.1 Generic Drugs
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Branded Drugs
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Hospital Pharmacies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Retail Pharmacies
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Online Pharmacies
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Europe
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Asia Pacific
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Middle East and Africa
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast
• 10.5 Latin America
  • 10.5.1 Market Trends
  • 10.5.2 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porter's Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Otsuka Pharmaceutical
  • 15.3.2 Pfizer
  • 15.3.3 Eli Lilly and Company
  • 15.3.4 AstraZeneca
  • 15.3.5 Novartis
  • 15.3.6 Bristol-Myers Squibb
  • 15.3.7 GlaxoSmithKline
  • 15.3.8 Takeda Pharmaceutical Company
  • 15.3.9 Allergan
  • 15.3.10 Johnson & Johnson
  • 15.3.11 Zhejiang NHU Company Ltd
  • 15.3.12 Sebela Pharmaceuticals